Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $605M | $148M | $190M | $134M | 40.2% | 37.1% | 436.6% |
| 2024 | $442M | $70M | $35M | $-81M | 15.5% | 82.7% | -241.7% |
| 2023 | $242M | $-8M | $-25M | $-192M | -18.2% | 158.5% | -30.9% |
| 2022 | $93M | $-29M | $-36M | $-58M | -19.3% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 605.49 |
| Operating Revenue | 605.49 |
| Cost Of Revenue | 242.69 |
| Gross Profit | 362.81 |
| Operating Expense | 254.22 |
| Research And Development | 69.06 |
| Selling General And Administration | 185.17 |
| Total Expenses | 496.91 |
| Operating Income | 108.58 |
| Total Operating Income As Reported | 108.58 |
| EBITDA | 148.49 |
| Normalized EBITDA | 148.49 |
| EBIT | 121.30 |
| Interest Income | - |
| Interest Expense | 13.78 |
| Net Interest Income | -13.78 |
| Other Non Operating Income Expenses | 12.72 |
| Other Income Expense | 12.72 |
| Interest Income Non Operating | - |
| Interest Expense Non Operating | 13.78 |
| Net Non Operating Interest Income Expense | -13.78 |
| Pretax Income | 107.52 |
| Tax Provision | -82.77 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income Continuous Operations | 190.29 |
| Net Income From Continuing And Discontinued Operation | 190.29 |
| Net Income From Continuing Operation Net Minority Interest | 190.29 |
| Net Income | 190.29 |
| Net Income Common Stockholders | 190.29 |
| Net Income Including Noncontrolling Interests | 190.29 |
| Normalized Income | 190.29 |
| Diluted NI Availto Com Stockholders | 190.29 |
| Basic Average Shares | 33.99 |
| Diluted Average Shares | 40.54 |
| Reconciled Depreciation | 27.18 |
| Reconciled Cost Of Revenue | 242.69 |
| Total Unusual Items | - |
| Total Unusual Items Excluding Goodwill | - |
| Special Income Charges | - |
| Other Special Charges | - |
| Gain On Sale Of Security | - |
| General And Administrative Expense | 180.85 |
| Other Gand A | 66.35 |
| Salaries And Wages | 114.51 |
| Selling And Marketing Expense | 4.32 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| TransMedics Group, Inc.this co. | TMDX | $2.5B | 12.96 | 5.21 | 40.2% | 16.82 |
| National HealthCare Corporation | NHC | $2.9B | 24.47 | 2.75 | 11.2% | 13.71 |
| Privia Health Group, Inc. | PRVA | $2.7B | 117.50 | 3.65 | 3.1% | 50.35 |
| Supernus Pharmaceuticals, Inc. | SUPN | $2.6B | -67.30 | 2.44 | -3.6% | 58.94 |
| Acadia Healthcare Company, Inc. | ACHC |
| - |
| - |
| - |
| - |
| - |
| - |
| $2.3B |
| -2.10 |
| 1.19 |
| -56.6% |
| -6.55 |
| Prestige Consumer Healthcare Inc. | PBH | $2.2B | 11.31 | 1.14 | 10.1% | 9.47 |
| LeMaitre Vascular, Inc. | LMAT | $2.1B | 37.03 | 5.43 | 14.7% | 25.28 |
| Select Medical Holdings Corporation | SEM | $2.0B | 13.99 | 1.20 | 8.6% | 9.20 |
| Neogen Corporation | NEOG | $2.0B | -1.82 | 0.96 | -52.7% | -2.94 |
| Peer Median | - | 12.65 | 1.82 | 5.8% | 11.59 | |